Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada.
Am J Clin Pathol. 2012 Jan;137(1):75-85. doi: 10.1309/AJCPMMLQ67YOMGEW.
Mantle cell lymphoma (MCL) and small lymphocytic lymphoma (SLL) exhibit similar but distinct immunophenotypic profiles. Many cases can be diagnosed readily by flow cytometry (FCM) alone; however, ambiguous cases are frequently encountered and necessitate additional studies, including immunohistochemical staining for cyclin D1 and fluorescence in situ hybridization for IgH-CCND1 rearrangement. To determine if greater diagnostic accuracy could be achieved from FCM data alone, we developed an unbiased, machine-based algorithm to identify features that best distinguish between the 2 diseases. By applying conventional diagnostic criteria to the flow cytometry data, we were able to assign 28 of 44 (64%) MCL and 48 of 70 (69%) SLL cases correctly. In contrast, we were able to assign all 44 (100%) MCL and 68 of 70 (97%) SLL cases correctly using a novel set of criteria, as identified by our automated approach. The most discriminating feature was the CD20/CD23 mean fluorescence intensity ratio, and we found unexpectedly that inclusion of FMC7 expression in the diagnostic algorithm actually reduced its accuracy. This study demonstrates that computational methods can be used on existing clinical FCM data to improve diagnostic accuracy and suggests similar computational approaches could be used to identify novel prognostic markers and perhaps subdivide existing or define new diagnostic entities.
套细胞淋巴瘤 (MCL) 和小淋巴细胞淋巴瘤 (SLL) 表现出相似但又不同的免疫表型特征。许多病例可以通过流式细胞术 (FCM) 单独诊断;然而,经常会遇到模棱两可的病例,需要进行额外的研究,包括 cyclin D1 的免疫组织化学染色和 IgH-CCND1 重排的荧光原位杂交。为了确定是否可以仅从 FCM 数据获得更高的诊断准确性,我们开发了一种无偏见的基于机器的算法,以识别最能区分这两种疾病的特征。通过将常规诊断标准应用于流式细胞术数据,我们能够正确分配 44 例 MCL 中的 28 例 (64%) 和 70 例 SLL 中的 48 例 (69%)。相比之下,我们能够使用我们的自动方法确定的一组新的标准,正确分配 44 例 MCL 中的所有病例 (100%) 和 70 例 SLL 中的 68 例 (97%)。最具鉴别力的特征是 CD20/CD23 平均荧光强度比,我们出乎意料地发现,在诊断算法中包含 FMC7 表达实际上降低了其准确性。这项研究表明,计算方法可以用于现有的临床 FCM 数据,以提高诊断准确性,并表明类似的计算方法可用于识别新的预后标志物,也许可以细分现有或定义新的诊断实体。